Navigation Links
DiagnoCure to host Q2 2009 earnings conference call and webcast
Date:5/27/2009

Ticker Symbol: CUR

QUEBEC CITY, May 27 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced today that the Company will release its second quarter 2009 financial results on June 8, 2009, at approximately 4:30 p.m. (EDT). This release will be followed by a conference call, which will be held on June 9, 2009, at 10:00 a.m. (EDT). The conference will begin with a brief presentation, followed by a question-and-answer period.

The event will be webcast live through DiagnoCure's website at www.diagnocure.com, through a link on the Investors page - Presentations and Conferences.

For those who wish to take part in the conference call for the Q&A period, please dial (514) 807-8791 (Montreal area), (416) 644-3414 (Toronto area) or the toll-free number (800) 733-7560.

For those unable to participate, a replay of the audio conference will also be available on DiagnoCure's website as of June 11, 2009, also through a link on the Investors page - Presentations and Conferences.

About DiagnoCure

DiagnoCure (TSX: CUR) is a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services that increase clinician and patient confidence in making critical treatment decisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc., launched in 2008 the Previstage(TM) GCC Colorectal Cancer Staging Test, the first GCC-based molecular test for the management of colorectal cancer. A major study published in the February 18, 2009, edition of the JAMA ("Journal of the American Medical Association") demonstrated that GCC, to which DiagnoCure secured exclusive worldwide diagnostic rights, is the strongest independent predictor of colorectal cancer recurrence. The Company has a strategic a
'/>"/>

SOURCE DiagnoCure Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. DiagnoCure announces first quarter 2009 results
2. New website empowers colorectal cancer patients when discussing critical treatment decisions - DiagnoCure launches www.mypersonalcancerdiagnosis.com
3. DiagnoCure to Host Q1 2009 Earnings Conference Call and Webcast
4. Major study on DiagnoCures GCC biomarker published in Jama
5. DiagnoCure announces fourth quarter 2008 and year-end results
6. DiagnoCure announces fourth quarter and full year 2008 earnings conference call and webcast
7. DiagnoCure to webcast presentation at the Piper Jaffray Health Care Conference on December 3, 2008
8. DiagnoCure to present at the JMP Securities Healthcare Focus Conference on October 6, 2008
9. Diagnocure announces sponsorship of inaugural undy 5,000 run - Partnership with the Colon Cancer Alliance creates patient awareness of previstage(TM) GCC staging test
10. DiagnoCures GCC marker for the staging of colorectal cancer discussed at the Eastern Cooperative Oncology Group
11. DiagnoCure announces second quarter 2008 results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... 2013 Due to the extremely high ... MileageAds.com has decided to invite bloggers and business owners ... network. , Businesses in the Mesothelioma sector have ... marketing, specifically with ad networks. , Thousands of ... services and are unsure where to turn. By using ...
(Date:5/19/2013)... the heterogeneity the variety of genetic mutations of ... patients with the most common type of head and neck ... Cancer , investigators at Massachusetts General Hospital (MGH) and ... a better predictor of survival than most traditional risk factors ... of the head and neck. , "Our findings ...
(Date:5/19/2013)... 2013) The American Gastroenterological Association (AGA) Research ... Award recipients. The awards are intended to stimulate ... high school, undergraduate, graduate and medical school students. ... Eli and Edythe Broad Foundation. , "The ... with unprecedented research opportunities," said Nicholas F. LaRusso, ...
(Date:5/19/2013)... Cheap Concert Tickets announces that Jimmy ... October will go on sale to the public Monday morning, ... of 2013, this legendary artist will be visiting prime venues ... Five O’clock Somewhere” they instantly remember the good old ... heads. Fortunately, fans can take a trip down memory lane ...
(Date:5/19/2013)... Berkeley Heights, NJ (PRWEB) May 20, 2013 ... Care have joined Summit Medical Group: David A. Abrutyn, ... They will continue to see patients at their current ... David A. Abrutyn, M.D., has expertise in sports medicine, ... He also treats pediatric, adolescent, and adult patients for ...
Breaking Medicine News(10 mins):Health News:Mileageads Ad Network Now Invites Bloggers and Business Owners in Mesothelioma Sector to Advertise on Their Ad Network 2Health News:Genetic diversity within tumors predicts outcome in head and neck cancer 2Health News:Genetic diversity within tumors predicts outcome in head and neck cancer 3Health News:AGA Student Research Fellowships enable 30 young investigators to further their research careers 2Health News:Jimmy Buffett Las Vegas Tickets: Jimmy Buffett Tickets in Vegas at the MGM Grand on Oct. 19 and Oct. 26 Go on Public Sale Monday, May 20 at 10:00 a.m. Local Time 2Health News:Jimmy Buffett Las Vegas Tickets: Jimmy Buffett Tickets in Vegas at the MGM Grand on Oct. 19 and Oct. 26 Go on Public Sale Monday, May 20 at 10:00 a.m. Local Time 3Health News:Summit Medical Group Welcomes the Center for Orthopedic Care 2Health News:Summit Medical Group Welcomes the Center for Orthopedic Care 3
... solutions to tackle obesity, the latest on the Northwick ... sport and the Olympics will be highlighted at ... Pharmacological Society (BPS), Europe,s leading pharmacological research society, is ... attracting experts from across the world. , Running from ...
... Public Relations Worldwide (Ogilvy PR), an integrated global communications ... five-year comprehensive communications support contract with the National Cancer ... will be performed by Ogilvy PR,s Washington, DC-based Social ... consulting subsidiary, Feinstein Kean Healthcare (FKH). , ...
... But American physicians often overlook the illness, delaying diagnosis ... doctors view leprosy as a scourge of Biblical times ... U.S. cases, with more diagnosed each year, experts say. ... remains a largely forgotten illness, U.S. physicians are often ...
... peginterferon in combination with ribavirin for previously untreated children ... , KENILWORTH, N.J., Dec. ... today announced that the U.S. Food and Drug Administration ... and REBETOL(R) (ribavirin, USP) combination therapy for use in ...
... ANN ARBOR, Mich., Dec. 12 Terumo Corporation ... that,they have entered into an agreement to settle ... companies have a number of lawsuits pending,in which ... The litigations all,involve methods and devices used ...
... Dec. 12 Dignitas Personae (The Dignity of ... Doctrine of the Faith (CDF) on ethical issues arising from ... and human procreation in our heavily scientific age, said Cardinal ... of Catholic Bishops. , , ...
Cached Medicine News:Health News:Leading pharmacologists to meet in Brighton 2Health News:National Cancer Institute Selects Ogilvy Public Relations Worldwide for Comprehensive Multi-Year Communications Support 2Health News:Leprosy Lingers in the U.S. 2Health News:Leprosy Lingers in the U.S. 3Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 2Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 3Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 4Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 5Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 6Health News:Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C 7Health News:Dignitas Personae, Vatican Instruction on Bioethics, Welcomed for Guidance on Issues of Procreation, Medical Research 2Health News:Dignitas Personae, Vatican Instruction on Bioethics, Welcomed for Guidance on Issues of Procreation, Medical Research 3Health News:Dignitas Personae, Vatican Instruction on Bioethics, Welcomed for Guidance on Issues of Procreation, Medical Research 4
(Date:5/17/2013)...  TechAtlas Group has announced the release of ... for the Chronic Kidney Disease (CKD) market. This ... drugs and devices currently on the market and ... (Logo:  http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ) ... renal denervation , diabetic nephropathy - antifibrotics ...
(Date:5/17/2013)... MIAMI LAKES, Fla. , May 17, 2013 ... products and delivery technology company that is developing new, patent-pending ... and minerals, announced today that it will hold a business ... on Wednesday, May 22 nd , 2013 at 4:30 PM ... Brian Tuffin will host the call and will ...
(Date:5/17/2013)... , May 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... study, JAKARTA , examining the selective ... endpoint in both dose groups. The primary endpoint assessed ... volume. Consistent with data reported in previous trials, the ... vomiting. Full results will be presented at an upcoming ...
Breaking Medicine Technology:TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
The entirely open modular system is especially suitable for stereotactic microsurgical procedures....
Used to negotiate tortuous vessels....
The Emerald Guidewire is intended for percutaneous introduction of catheters....
... The MULTI-LINK VISION Coronary Stent System is ... cobalt chromium stents. Cobalt chromium is stronger ... a cobalt chromium stent can have similar ... steel stent with struts that are only ...
Medicine Products: